arrow
F

Federico Cappuzzo

azienda ospedaliera universitaria integrata verona
H指数:88
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

伊沃奈司单抗联合化疗与安慰剂联合化疗在EGFR突变型晚期非小细胞肺癌患者中的疗效比较(患者既往接受EGFR酪氨酸激酶抑制剂治疗后疾病进展)(HARMONi研究):一项多中心、随机、双盲、Ⅲ期临床试验

2026-08-240
PRE
High Prevalence of Superficial Metastases Supports Percutaneous Ultrasound-Guided Biopsy for Diagnosis and Molecular Profiling of Advanced Lung Cancer: Results from a Prospective Cohort

浅表转移的高发生率支持经皮超声引导活检用于晚期肺癌的诊断和分子分型:一项前瞻性队列研究的结果

Cancers
IF4.4
2026-07-230
OA
Corrigendum to “A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma” [Exp Mol Pathol Volume 146, June 2026, 105049]

勘误:WNT/β-连环蛋白相关转录程序可预测肝癌患者的生存结局 [Exp Mol Pathol Volume 146, June 2026, 105049]

2026-05-280
OAAI
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma

WNT/β-连环蛋白相关转录程序可预测肝细胞癌患者的生存结局

2026-05-110
OAAI
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations

非小细胞肺癌分子亚型和免疫治疗组合的脆弱性

2025-12-030
OAAI
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

II期、多中心、开放标签、单臂研究:伯佐塞替联合拓扑替康治疗复发铂耐药小细胞肺癌患者(DDRiver SCLC 250)

2025-12-010
OAAI
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer

IMscin002研究:非小细胞肺癌患者对阿替利珠单抗皮下给药与静脉给药的偏好探索性分析

2025-11-260
OAAI
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials

EGFR突变非小细胞肺癌的一线治疗:一项基于个体患者数据的Ⅲ期临床 trial 比较的简报

2025-11-190
OAAI
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study

一线Sacituzumab Govitecan联合Pembrolizumab治疗转移性NSCLC:EVOKE-02研究PD-L1 TPS <50%和≥50%队列

2025-10-300
PRE
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study

简要报告:IPSOS III期研究中非小细胞肺癌铂类不适用性的事后验证

2025-07-220
PRE
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma

TP53共突变增加了EGFR突变的Ⅰ期肺腺癌的复发风险。

2025-07-100
PRE
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer

DNA甲基转移酶3A(DNMT3A)突变与非小细胞肺癌中PD-(L)1阻断疗法的疗效

2025-06-180
PRE
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC

空间转录组学凸显B细胞作为对可切除非小细胞肺癌患者化疗免疫治疗产生完全且持久应答的关键贡献者。

2025-05-110
OA